IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region

Abstract

Background

Isocitrate dehydrogenase (IDH) mutation has diagnostic and prognostic values in glioblastomas. Peritumoral invasion of glioma cells is a cardinal feature of glioblastomas.

Purpose

To evaluate the contribution of DWI and DSC-PWI in the enhancing and peri-enhancing region for discriminating glioblastomas IDH genotypes, and the diagnostic values of combining two techniques in the peri-enhancing region compared with those in the enhancing region.

Material and Methods

We retrospectively reviewed the conventional MRI (cMRI), DWI and DSC-PWI obtained from 10 patients with IDH-mutated (IDH-m) glioblastomas and 65 patients with IDH wild-type (IDH-w) glioblastomas. Features of cMRI, relative minimum ADC in the enhancing region (rADC_min-t) and peri-enhancing area (rADC_min-p), and relative maximum CBV values in the enhancing region (rCBV_max-t) and peri-enhancing region (rCBV_max-p) were compared between two groups. Receiver operating characteristic curves and logistic regression analysis were used to assess diagnostic performance.

Results

IDH-m glioblastomas tended to present in frontal lobes and younger patients. The rADC_min-t (P = 0.042) were significantly lower in IDH-w than IDH-m. Both rCBV_max-t and rCBV_max-p showed significant differences between two subgroups (all P < 0.001). The optimal cutoff values in prediction of IDH-m were >0.98 for rADC_min-t, <7.27 for rCBV_max-t, and < 0.97 for rCBV_max-p. Multivariate logistic regression revealed that the combination of rADC_min-t and rCBV_max-t yielded the highest sensitivity and specificity.

Conclusion

The rCBV_max-t or rCBV_max-p may serve as preferable and comparable imaging biomarkers for evaluation of glioblastomas IDH status. The combination of rADC_min-t and rCBV_max-t may yield the maximum predictive power for differentiating IDH status.

Keywords

Glioblastomas isocitrate dehydrogenase mutational status diffusion-weighted imaging dynamic susceptibility contrast-perfusion weighted imaging conventional magnetic resonance imaging

Get full access to this article

View all access options for this article.

References

Berens

Giese

“…those left behind.” Biology and oncology of invasive glioma cells.

Neoplasia 1999; 1:208–219.

Louis

Perry

Reifenberger

, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131:803–820.

Hartmann

Hentschel

Wick

, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120:707–718.

Omuro

Beal

Gutin

, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 2014; 20:5023–5031.

Yang

Zhang

Wang

, et al. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget 2015; 6:40896–40906.

Dang

Jin

SM.

IDH mutations in glioma and acute myeloid leukemia.

Trends Mol Med 2010; 16:387–397.

Beiko

Suki

Hess

, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014; 16:81–91.

Carrillo

Lai

Nghiemphu

, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol 2012; 33:1349–1355.

Liu

Mangla

Tian

, et al. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma. J Neurooncol 2017; 135:553–560.

10.

Yamashita

Hiwatashi

Togao

, et al. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status. Am J Neuroradiol 2016; 37:58–65.

11.

Kickingereder

Sahm

Radbruch

, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015; 5:16238.

12.

Drabycz

Roldán

de Robles

, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010; 49:1398–1405.

13.

Sonoda

Shibahara

Kawaguchi

, et al. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 2015; 32:99–104.

14.

Svolos

Tsolaki

Kapsalaki

, et al. Investigating brain tumor differentiation with diffusion and perfusion metrics at 3T MRI using pattern recognition techniques. Magn Reson Imaging 2013; 31:1567–1577.

15.

Tan

Huang

Yin

, et al. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. Am J Neuroradiol 2014; 35:920–927.

16.

Lee

Choi

Ryoo

, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015; 121:141–150.

17.

Hong

Choi

Shin

, et al. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. Eur Radiol 2018; 28:4350–4361.

18.

Tan

Xiong

Huang

, et al. Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging 2017; 45:492–499.

19.

Xing

Yang

Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging.

Am J Neuroradiol 2017; 38:1138–1144.

20.

Parsons

Jones

Zhang

, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807–1812.

21.

Yan

Parsons

Jin

, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765–773.

22.

Zhang

Chang

Ramkissoon

, et al. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 2017; 19:109–117.

23.

Bralten

Kloosterhof

Balvers

, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 2011; 69:455–463.

24.

Wang

Dong

Gao

, et al. Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells. Oncol Lett 2014; 7:651–657.

25.

Losman

Looper

Koivunen

, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339:1621–1625.

26.

Koivunen

Lee

Duncan

, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483:484–488.

27.

Wang

Kim

Chawla

, et al. Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 2009; 44:653–660.

28.

Guo

Chen

, et al. Direct measurement of the signal intensity of diffusion-weighted magnetic resonance imaging for preoperative grading and treatment guidance for brain gliomas. J Chin Med Assoc 2012; 75:581–588.

29.

Lehmann

Saliou

de Marco

, et al. Cerebral peritumoral oedema study: does a single dynamic MR sequence assessing perfusion and permeability can help to differentiate glioblastoma from metastasis? Eur J Radiol 2012; 81:522–527.

30.

Jabehdar Maralani

Melhem

Wang

, et al. Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas. Eur Radiol 2015; 25:2738–2744.